Israel Carsten W, Sheta Mohamed Karim
Klinik für Innere Medizin - Kardiologie, Diabetologie & Nephrologie, Evangelisches Krankenhaus Bielefeld, Burgsteig 13, 33617, Bielefeld, Deutschland,
Herzschrittmacherther Elektrophysiol. 2015 Jun;26(2):94-104. doi: 10.1007/s00399-015-0375-5.
Implantable cardioverter-defibrillator (ICD) leads have to fulfill particular requirements: safe pacing and sensing, detection, and termination of ventricular tachyarrhythmias, if necessary by (multiple) high-energy shocks. At the same time, their implantation has to be simple, they need to provide excellent long-term stability and they must be completely and safely extractable. Numerous technical developments have enabled currently available ICD leads to fulfill these expectations to a high extent. However, some changes of lead design, materials, and manufacturing processes have led to increased lead failure, especially in two lead models (Medtronic Sprint Fidelis®, St. Jude Medical Riata®). The high rate of lead failure was identified only several years after market release, in part because there are no appropriate registries of ICD leads. This review presents background and developments of ICD lead technology and their association with the clinical usage of ICD therapy. To also benefit patients with only slightly-to-moderately increased risk of ventricular tachyarrhythmia, optimum ICD therapy requires optimal leads and sufficiently experienced implanters.
植入式心脏复律除颤器(ICD)导线必须满足特定要求:安全起搏和感知、检测并终止室性快速心律失常,必要时通过(多次)高能电击来实现。与此同时,其植入过程必须简单,需要具备出色的长期稳定性,并且必须能够完全且安全地取出。众多技术发展使得当前可用的ICD导线在很大程度上满足了这些期望。然而,导线设计、材料和制造工艺的一些变化导致导线故障增加,尤其是在两种导线型号(美敦力Sprint Fidelis®、圣犹达医疗Riata®)中。导线故障率在上市几年后才被发现,部分原因是缺乏合适的ICD导线注册登记。本综述介绍了ICD导线技术的背景和发展及其与ICD治疗临床应用的关联。为了使室性快速心律失常风险仅略有或中度增加的患者也能受益,最佳的ICD治疗需要最佳的导线和经验丰富的植入者。